Papers by Leopoldo Piegas
Circulation, 1998
Background —Unstable angina and non–Q-wave myocardial infarction involve coronary arterial plaque... more Background —Unstable angina and non–Q-wave myocardial infarction involve coronary arterial plaque rupture, platelet activation, and thrombus formation. This study tested the benefit of different doses of lamifiban (a platelet IIb/IIIa antagonist) alone and in combination with heparin in patients with these conditions to select the most promising lamifiban regimen for subsequent evaluation. Methods and Results —At 273 hospitals in 20 countries, 2282 patients were randomly assigned to lamifiban (2×2 factorial design: low-dose [1 μg/min] with and without heparin versus high-dose [5 μg/min] with and without heparin) or to standard therapy (placebo and heparin). All patients received aspirin. The composite primary end point of death or nonfatal myocardial infarction at 30 days occurred in 11.7% of those receiving standard therapy, 10.6% receiving low-dose lamifiban, and 12.0% receiving high-dose lamifiban ( P =0.668). By 6 months, this composite was lowest for those assigned to low-dose ...
Bookmarks Related papers MentionsView impact
Arquivos Brasileiros de Cardiologia, 2013
Bookmarks Related papers MentionsView impact
Arquivos Brasileiros de Cardiologia, 2009
Bookmarks Related papers MentionsView impact
The American Journal of Cardiology, 1974
ABSTRACT
Bookmarks Related papers MentionsView impact
Arquivos Brasileiros De Cardiologia, Apr 1, 2011
Bookmarks Related papers MentionsView impact
The New England journal of medicine, Jan 2, 2016
Background Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increas... more Background Elevated blood pressure and elevated low-density lipoprotein (LDL) cholesterol increase the risk of cardiovascular disease. Lowering both should reduce the risk of cardiovascular events substantially. Methods In a trial with 2-by-2 factorial design, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to rosuvastatin (10 mg per day) or placebo and to candesartan (16 mg per day) plus hydrochlorothiazide (12.5 mg per day) or placebo. In the analyses reported here, we compared the 3180 participants assigned to combined therapy (with rosuvastatin and the two antihypertensive agents) with the 3168 participants assigned to dual placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included heart failure, cardiac arrest, or revascularization. The median follow-up was 5.6 years. Results The decreas...
Bookmarks Related papers MentionsView impact
The New England journal of medicine, Jan 2, 2016
Background Previous trials have shown that the use of statins to lower cholesterol reduces the ri... more Background Previous trials have shown that the use of statins to lower cholesterol reduces the risk of cardiovascular events among persons without cardiovascular disease. Those trials have involved persons with elevated lipid levels or inflammatory markers and involved mainly white persons. It is unclear whether the benefits of statins can be extended to an intermediate-risk, ethnically diverse population without cardiovascular disease. Methods In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants in 21 countries who did not have cardiovascular disease and were at intermediate risk to receive rosuvastatin at a dose of 10 mg per day or placebo. The first coprimary outcome was the composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, and the second coprimary outcome additionally included revascularization, heart failure, and resuscitated cardiac arrest. The median follow-up was 5.6 years. Results The over...
Bookmarks Related papers MentionsView impact
Arquivos Brasileiros de Cardiologia, 2015
Bookmarks Related papers MentionsView impact
Arquivos brasileiros de cardiologia, 2007
To evaluate the occurrence of variables detecting myocardial ischemia during or after dental trea... more To evaluate the occurrence of variables detecting myocardial ischemia during or after dental treatment under anesthesia with vasoconstrictor (epinephrine). A total of 54 coronary patients undergoing dental extraction under local anesthesia with or without vasoconstrictor were included. They were divided into two groups (by drawing envelopes): group I (27 patients) using anesthetics with vasoconstrictor, and group II (27 cases) without vasoconstrictor. 24-hour Holter monitoring, Doppler-echocardiogram before and after dental intervention, and determination of biochemical markers (CK-MB mass, CK-MB activity, and troponin T) before and 24 hours after dental extraction were performed in all patients. Heart rate and blood pressure were also measured in the pre, post-anesthesia and post-dental extraction phases. Doppler echocardiography assessed left ventricular segmental contractility and the occasional occurrence of mitral regurgitation. The usual pharmaceutical treatment prescribed by ...
Bookmarks Related papers MentionsView impact
Revista Brasileira de Terapia Intensiva, 2008
Bookmarks Related papers MentionsView impact
Arquivos Brasileiros de Cardiologia, 2014
Bookmarks Related papers MentionsView impact
The Journal of Emergency Medicine, 2011
Bookmarks Related papers MentionsView impact
Japanese Heart Journal, 1986
Bookmarks Related papers MentionsView impact
Japanese Heart Journal, 1988
Bookmarks Related papers MentionsView impact
Circulation, 2008
Background— The Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 ... more Background— The Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) trials evaluated fondaparinux, a synthetic factor Xa inhibitor, in patients with non–ST- and ST-segment elevation acute coronary syndromes, respectively. Combined results for these 2 trials on major efficacy and safety outcomes and data on the effects of fondaparinux in relation to interventional management strategy have not been previously reported. Methods and Results— We performed an individual patient–level combined analysis of 26 512 patients from the OASIS 5 and 6 trials who were randomized in a double-blind fashion to fondaparinux 2.5 mg daily or a heparin-based strategy (dose-adjusted unfractionated heparin or enoxaparin). Results were stratified according to whether an early invasive, a delayed invasive, or an initial conservative management strategy was performed. Fondaparinux was superior to heparin in reducing the composite of death, myocardial infarction, or stroke (8...
Bookmarks Related papers MentionsView impact
BMJ, 2011
Bookmarks Related papers MentionsView impact
Arquivos Brasileiros de Cardiologia, 2007
Bookmarks Related papers MentionsView impact
Arquivos Brasileiros de Cardiologia, 2004
Bookmarks Related papers MentionsView impact
Arquivos Brasileiros de Cardiologia, 2007
Bookmarks Related papers MentionsView impact
Arquivos Brasileiros de Cardiologia, 2004
Bookmarks Related papers MentionsView impact
Uploads
Papers by Leopoldo Piegas